About Zinc finger protein 382
Zinc finger protein 382 (ZNF382) is a protein
from Homo sapiens identified by UniProt accession
Q96SR6, 550 residues long.
MolForge cross-references it against 0 known binders and
31 disease associations.
Target properties
| Protein name | Zinc finger protein 382 |
| UniProt accession | Q96SR6 |
| Gene | ZNF382 |
| Organism | Homo sapiens |
| Length | 550 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (31)
Diseases linked to this target (Open Targets).
- gonorrhea · score 0.08
- esophageal squamous cell carcinoma · score 0.08
- acute myeloid leukemia · score 0.07
- neoplasm · score 0.07
- mean corpuscular volume · score 0.04
- stomach neoplasm · score 0.02
- pancreatic neoplasm · score 0.02
- hepatocellular carcinoma · score 0.01
- carcinoma · score 0.01
- Sepsis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96SR6-F1 | alphafold | PREDICTED | 62.72 | — |
Amino-acid sequence (550 residues)
MPLQGSVSFK DVTVDFTQEE WQQLDPAQKA LYRDVMLENY CHFVSVGFHM AKPDMIRKLE QGEELWTQRI FPSYSYLEED GKTEDVLVKF KEYQDRHSRP LIFINHKKLI KERSNIYGKT FTLGKNRISK TILCEYKPDG KVLKNISELV IRNISPIKEK FGDSTGWEKS LLNTKHEKIH PAVNLHKQTE RVLSGKQELI QHQKVQAPEQ PFDHNECEKS FLMKGMLFTH TRAHRGERTF EYNKDGIAFI EKSSLSVHPS NLMEKKPSAY NKYGKFLCRK PVFIMPQRPQ TEEKPFHCPY CGNNFRRKSY LIEHQRIHTG EKPYVCNQCG KAFRQKTALT LHEKTHIEGK PFICIDCGKS FRQKATLTRH HKTHTGEKAY ECPQCGSAFR KKSYLIDHQR THTGEKPYQC NECGKAFIQK TTLTVHQRTH TGEKPYICNE CGKSFCQKTT LTLHQRIHTG EKPYICNECG KSFRQKAILT VHHRIHTGEK SNGCPQCGKA FSRKSNLIRH QKTHTGEKPY ECKQCGKFFS CKSNLIVHQK THKVETTGIQ
Explore Zinc finger protein 382 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets